Leshanth Uthayanan1, Mona El-Bahrawy2,3. 1. Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, W12 0NN, UK. 2. Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, W12 0NN, UK. m.elbahrawy@imperial.ac.uk. 3. Department of Pathology, Alexandria Faculty of Medicine, Alexandria, Egypt. m.elbahrawy@imperial.ac.uk.
Abstract
BACKGROUND: Ovarian cancer has the highest mortality amongst all gynaecological malignancies, with around two-thirds of patients diagnosed with advanced disease due to late presentation. Furthermore, around 90% of patients develop recurrence and eventually become chemoresistant. Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. Tight junctions (TJs) regulate paracellular permeability and are vital in establishing epithelial cell polarity. One hallmark of tumorigenesis is the loss of TJs, with loss of cell-to-cell adhesion. Claudins are integral TJ membrane proteins, which have been found to play a critical role in maintaining the TJ's barrier function. Furthermore, claudin-3 (CLDN3) and claudin-4 (CLDN4) are overexpressed in ovarian cancer. This article aims to explore the biological role of CLDN3 and CLDN4 and their potential in different aspects of the management of ovarian cancer. MAIN BODY: CLDN3 and CLDN4 have been shown to be effective markers for the early detection of ovarian cancer. Whilst there is difficulty in screening for both claudins in serum, their assessment by gene expression analysis and immunohistochemical methods shows promising potential as diagnostic and prognostic biomarkers for ovarian cancer. The localisation and overexpression of claudins, such as CLDN3, have been shown to correlate with poorer survival outcomes. The added value of combining claudins with other markers such as CA125 for diagnosis has also been highlighted. Therapeutically, CLDN3 and more so CLDN4 have been shown to be effective targets of Clostridium perfringens enterotoxin (CPE). Interestingly, CPE has also been shown to resensitise chemoresistant tumours to therapy. CONCLUSIONS: This review presents the diagnostic and prognostic potential of CLDN3 and CLDN4 and their emerging role as therapeutic targets in ovarian cancer. Clinical trials are required to validate the promising results of the in vitro and in vivo studies for CLDN3 and CLDN4, possibly adding onto current ovarian cancer management.
BACKGROUND: Ovarian cancer has the highest mortality amongst all gynaecological malignancies, with around two-thirds of patients diagnosed with advanced disease due to late presentation. Furthermore, around 90% of patients develop recurrence and eventually become chemoresistant. Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. Tight junctions (TJs) regulate paracellular permeability and are vital in establishing epithelial cell polarity. One hallmark of tumorigenesis is the loss of TJs, with loss of cell-to-cell adhesion. Claudins are integral TJ membrane proteins, which have been found to play a critical role in maintaining the TJ's barrier function. Furthermore, claudin-3 (CLDN3) and claudin-4 (CLDN4) are overexpressed in ovarian cancer. This article aims to explore the biological role of CLDN3 and CLDN4 and their potential in different aspects of the management of ovarian cancer. MAIN BODY: CLDN3 and CLDN4 have been shown to be effective markers for the early detection of ovarian cancer. Whilst there is difficulty in screening for both claudins in serum, their assessment by gene expression analysis and immunohistochemical methods shows promising potential as diagnostic and prognostic biomarkers for ovarian cancer. The localisation and overexpression of claudins, such as CLDN3, have been shown to correlate with poorer survival outcomes. The added value of combining claudins with other markers such as CA125 for diagnosis has also been highlighted. Therapeutically, CLDN3 and more so CLDN4 have been shown to be effective targets of Clostridium perfringens enterotoxin (CPE). Interestingly, CPE has also been shown to resensitise chemoresistant tumours to therapy. CONCLUSIONS: This review presents the diagnostic and prognostic potential of CLDN3 and CLDN4 and their emerging role as therapeutic targets in ovarian cancer. Clinical trials are required to validate the promising results of the in vitro and in vivo studies for CLDN3 and CLDN4, possibly adding onto current ovarian cancer management.
Authors: Babak Litkouhi; Joseph Kwong; Chun-Min Lo; James G Smedley; Bruce A McClane; Margarita Aponte; Zhijian Gao; Jennifer L Sarno; Jennifer Hinners; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner Journal: Neoplasia Date: 2007-04 Impact factor: 5.715
Authors: Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner Journal: Mol Cancer Res Date: 2019-01-03 Impact factor: 5.852
Authors: Leticia B A Rangel; Rachana Agarwal; Theresa D'Souza; Ellen S Pizer; Piero L Alò; Wayne D Lancaster; Lucie Gregoire; Donald R Schwartz; Kathleen R Cho; Patrice J Morin Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Y-L Choi; J Kim; M J Kwon; J S Choi; T-J Kim; D-S Bae; S S Koh; Y-H In; Y W Park; S H Kim; G Ahn; Y K Shin Journal: Histol Histopathol Date: 2007-11 Impact factor: 2.303
Authors: Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-13 Impact factor: 4.254